Andrew Hui

Testing a longer-form research format away from the usual slide decks on bio-data for model training. Putting some highlights in the thread. demandrew.com/publish/post/1…

@buccocapital Peloton up because Anthropic enables better workouts..?

“The Market” is just a guy staring a two screens. One has Truth Social. The other is Anthropic's blog In front of him are 5 buttons that say: Software, Semis, European Defense, Energy, and Gold. Trump or Anthropic post and he hits a button to make those stocks move +5% or -5%

@mkoeris Similar findings from this recent preprint as well arxiv.org/pdf/2603.05532

I trust what DL writes

@MelindaBChu1 the ones that do pivot to drug development end up crowding the same targets anyways (e.g. PI3Ka mutant inhibitors)

This blew my mind. 🤯 I always thought based on media / hype that with new AI /Tech Bio companies were that you have idea, start the project, get list of compounds, synthesize them, ➡️ automated lab ➡️ Phase 1 human study, and then “cure ALL diseases in 5-10 years.” That’s what people say. 🚨 So I figured most TechBio would have to pivot to drug development b/c that’s wheee th real value in Biotech is and there’s not enough customers (other than Big Pharma) for all these SaaS. 🚨BUT looking into this, I learned that most companies only do 1 small step in drug design, so in theory you would need 6-10 of them to actually get to compound synthesis. 🚨This means 2 things: 1.). Means they can’t really pivot to developing drug assets b/c it’s only 1 small step of process. 2.) Reinforces my view that there aren’t enough customers for each SaaS 🌟 Check out this technical paper where I go into this in more detail and demonstrate my multi-model orchestration approach.

@packyM had a sick lab tour last year from them, very cool work

I am so clucking eggcited that Neion Bio is finally coming out of its shell. 🐣 Today, pharma uses Chinese hamster ovary (CHO) cells to produce biologics like Keytruda and Humira in huge stainless steel bioreactors. Merck spent $1B on a single Keytruda facility. In early 2024, Elliot Hershberg wrote that chicken eggs are much more efficient bioreactors. They run on grain and water, produce six grams of protein per unit, and we already farm them at massive scale. Sam Levin, who we previously backed at Melonfrost, and Dimi Kellari explored the frontiers of this research, which they could get their arms around because the cutting edge stuff is happening in a very small number of labs around the world. They realized that the time was right to build a company that uses nature's bioreactors to produce drugs at a fraction of the cost. In today's NYT article, Sam predicts that the cost can be 1/10th or even 1/100th of the current cost, and that just 3,900 hens could meet global Humira demand. I'm proud to back Sam, Dimi, and the Neion Bio team as they work to hatch the balk of the world's biologics and dramatically lower the cost to produce critical drugs, right here in NYC. And I'm sure they're happy that I can share my chicken puns with all of you instead of just replying to investor updates with them. Check out what they're up to in the NYT article below.

Biotech funding (US/China/Global)

China biotech funding

TL;DR AI performance is tied to scaling laws, which means more data going in, hence, "data problems". The next wave of value creation will be tied to new sources of data that explore new biological space. But the issue is that this data isn't readily available for the industry.

8/ Scaling generative models drives the cost of hypothesis generation to zero. However, the key is still wet lab validation. The gap between hypothesis generation and wet lab validation creates "speculation debt" that still needs to be bridged

Testing a longer-form research format away from the usual slide decks on bio-data for model training. Putting some highlights in the thread. demandrew.com/publish/post/1…

@SynBio1 working as hard as possible to make this box bigger!!

AI makes biologic discovery easy. Development is faster and cheaper in China So the obvious play is "make fast followers with AI and do all the development in China" This is that play. It's a $787 M bet that “China + AI” is the future of biopharma prnewswire.com/news-releases/…

@JulianKlymochko Rare, elusive non-oil and gas exit in Calgary, too

What we have here is a rare, elusive, rarely seen private equity exit, with KKR monetizing its investment in CoolIT Systems for a cool $4.75 billion from Ecolab $ECL. Looks like a homerun deal for the firm.

@alexkesin genentech when?

Approved episode #2 out now: Geron They trailblazed longevity biotech in the '90s, cloned telomerase, funded early hESC work - and after 34 years got the first telomerase inhibitor approved for a rare blood cancer. Full story on the pod.

@maxxyung11 Now do it again

+90% @backshui